CHICAGO — A split-dose approach to the standard R-CHOP chemotherapy regimen resulted in a 71% complete response rate among Older Adults with newly diagnosed diffuse large B-cell lymphoma, results from a phase 2 study showed.
Data from the trial presented at ASCO Annual Meeting suggested that a more tolerable fractionated approach to a treatment regimen comprising rituximab (Rituxan, Genentech) plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) is feasible to deliver without compromising efficacy, investigators noted.
“Split-dose R-CHOP offers a new approach to